Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. Issue 11 (29th October 2014)

• Record Type: Journal Article
• Authors: Yao, Min; Galanopoulos, Nicholas; Lavertu, Pierre; Fu, Pingfu; Gibson, Michael; Argiris, Athanassios; Rezaee, Rod; Zender, Chad; Wasman, Jay; Machtay, Mitchell; Savvides, Panos
• Is Part Of: Head & neck. Volume 37:Issue 11(2015:Nov.)
• Page Start: 1665
• Page End: 1671
• Publication Date: 2014-10-29
• Subjects: Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.23813
• Languages: English
• ISSNs: 1043-3074

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="hed23813-sec-0001" sec-type="section"> <title>Background</title> <p>The purpose of this study was to establish the efficacy and toxicities of concurrent bevacizumab and docetaxel with radiation for locally advanced head and neck squamous cell carcinoma (HNSCC).</p> </sec> <sec id="hed23813-sec-0002" sec-type="section"> <title>Methods</title> <p>Patients with previously untreated HNSCC received standard daily radiotherapy (RT) with concurrent weekly docetaxel (20 mg/m<sup>2</sup>) and biweekly bevacizumab (5 mg/kg). Biweekly bevacizumab was then continued for up to 1 year after RT. The primary objective was progression‐free survival (PFS). Secondary objectives included overall survival (OS), patterns of failure, and toxicities of treatment.</p> </sec> <sec id="hed23813-sec-0003" sec-type="section"> <title>Results</title> <p>Thirty patients were recruited. With median follow‐up of 38 months, the 3‐year PFS, OS, locoregional recurrence‐free survival, and distant metastasis‐free survival was 61.7%, 68.2%, 84.5%, and 80.5%, respectively. The most common local toxicities were mucositis and dermatitis. Two patients developed hemorrhage. There was no grade 5 toxicity.</p> </sec> <sec id="hed23813-sec-0004" sec-type="section"> <title>Conclusion</title> <p>The combination of bevacizumab, docetaxel, and RT is tolerable and effective in HNSCC. This regimen is worthy of further study in appropriate subset of patients receiving chemoradiation therapy. © 2014 Wiley Periodicals, Inc. <italic>Head Neck</italic> 37: 1665–1671, 2015</p> </sec> </abstract>